openPR Logo
Press release

IVIG Market Growth is booming in next 10 years | Behring GmbH, Shanghai RAAS Blood Products Co., Ltd

01-28-2025 09:52 AM CET | Health & Medicine

Press release from: Allied Market Research

/ PR Agency: Allied Market Research
IVIG Market Growth is booming in next 10 years | Behring GmbH,

Immunoglobulins (IGs) are glycoproteins produced in the blood plasma in response to antigens, which are foreign to the host system. They are highly complex entities and specific in their action. They are obtained from blood by fractionation process and purified for therapeutic and nontherapeutic applications. Different classes of immunoglobulin such as IgG, IgA, and IgM are used for the treatment of various immunological and neurological diseases.

Request Sample Report at:

https://www.alliedmarketresearch.com/request-sample/325

The major factors driving the growth of the intravenous immunoglobulin market includes significant rise in geriatric population & number of hemophilic patients, improved technologies pertaining to the immunoglobulin production, and enhanced purification techniques (with better plasma yield). Furthermore, surge in prevalence diseases such as chronic inflammatory demyelinating polyneuropathy (CIDP), hypogammaglobulinemia, and others is expected to boost the market growth. However, stringent government regulations toward the use of intravenous immunoglobulin products and high risk of side effects associated with them are expected to hamper the growth of the market. On the contrary, high adoption of intravenous immunoglobulins for the treatment of various diseases is expected to create lucrative opportunities in the near future.

Application segment review:

Based on application, the global intravenous immunoglobulin market is divided into hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy, immunodeficiency diseases, myasthenia gravis, multifocal motor neuropathy, idiopathic thrombocytopenic purpura, inflammatory myopathies, specific antibody deficiency, Guillain-Barre syndrome, and others. The hypogammaglobulinemia segment was the highest contributor to the market in 2017, and is anticipated to maintain its dominance throughout the forecast period. This is attributed to the significant rise in the prevalence of hypogammaglobulinemia disorder across the globe over the years. For instance, hypogammaglobulinemia is the most common chronic immune defect in patients with lymphoproliferative disorders (LPDs). Its incidence rate is ~2 per 100,000 population yearly, globally.

Region segment review

Based on region, the intravenous immunoglobulin market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America is the largest contributor toward the global market, followed by Asia-Pacific. These regions collectively occupy almost 75% of the global market revenue. Presence of the largest plasma production facilities and high adoption rate in the developed countries majorly boost the market growth. However, LAMEA is projected to register the highest growth rate during the forecast period.

The report provides extensive competitive analysis and profiles of key market players that includes Baxter international Inc., CSL Ltd., Grifols S.A, Octapharma AG, Kedrion Biopharma Inc., LFB group, Biotest AG, China Biologics Products, Inc., Takeda Pharmaceuticals, and Bayer Healthcare.

Other players in the value chain include Hualan Biological Engineering Inc., Omrix Biopharmaceuticals Ltd., Behring GmbH, Shanghai RAAS Blood Products Co., Ltd., Option Care Enterprises, Inc., ADMA Biologics, Inc., and BioScrip, Inc.

For Purchase Enquiry at:

https://www.alliedmarketresearch.com/purchase-enquiry/325

Key Benefits for Intravenous Immunoglobulin Market:

The study provides an in-depth analysis of the global intravenous immunoglobulin market with the current trends and future estimations to elucidate the imminent investment pockets.

A comprehensive analysis of the factors that drive and restrict the market growth is provided.

A comprehensive quantitative analysis of the industry is provided from 2018 to 2025 to assist stakeholders to capitalize on the prevailing market opportunities.

An extensive analysis of the key segments of the industry helps to understand the trends in the global allergy treatment market.

Key players and their strategies are provided to understand the competitive outlook of the industry.

Contact

David Correa

1209 Orange Street,

Corporation Trust Center,

Wilmington, New Castle,

Delaware 19801 USA.

Toll Free: +1-800-792-5285

Int'l: +1-503-894-6022

UK: +44-845-528-1300

Hong Kong: +852-301-84916

India (Pune): +91-20-66346060

Fax: +1-855-550-5975

help@alliedmarketresearch.com

Web: https://www.alliedmarketresearch.com

About Allied Market Research:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release IVIG Market Growth is booming in next 10 years | Behring GmbH, Shanghai RAAS Blood Products Co., Ltd here

News-ID: 3836666 • Views:

More Releases from Allied Market Research

Herbal Die tary Supplement Market Size, Industry Analysis, Growth Drivers, Opportunities and Leading Players
Herbal Die tary Supplement Market Size, Industry Analysis, Growth Drivers, Oppor …
The herbal die tary supplement market size was valued at $11 billion in 2022, and is estimated to reach $21.4 billion by 2032, growing at a CAGR of 7.1% from 2023 to 2032. Herbal die tary supplements are natural items made from plants or plant extracts that are taken to supplement the diet and improve health and well-being. These supplements frequently contain a combination of vitamins, minerals, amino acids, and other
Mobile Application Security Market Growing at 26.3% CAGR Reach USD 37.1 Billion by 2032
Mobile Application Security Market Growing at 26.3% CAGR Reach USD 37.1 Billion …
Allied Market Research published a new report, titled, "Mobile Application Security Market Growing at 26.3% CAGR Reach USD 37.1 Billion by 2032." The report offers an extensive analysis of key growth strategies, drivers, opportunities, key segments, Porter's Five Forces analysis, and competitive landscape. This study is a helpful source of information for market players, investors, VPs, stakeholders, and new entrants to gain a thorough understanding of the industry and determine
MarTech Market Witnessing CAGR of 18.5% Hit USD 1.7 Trillion by 2032
MarTech Market Witnessing CAGR of 18.5% Hit USD 1.7 Trillion by 2032
The global marketing technology market is experiencing growth due to several factors, including the increasing digital transformation, the surge in demand for personalized experience, and the proliferation of automation and efficiency. However, data privacy and compliance, and the high cost of implementation are expected to hamper market growth. Furthermore, the growing integration of AI and ML technologies and the increase in demand for real-time marketing are anticipated to provide lucrative
Feedback Management Software Market Growing with CAGR of 12.9% Reach USD 28.7 Billion by 2031
Feedback Management Software Market Growing with CAGR of 12.9% Reach USD 28.7 Bi …
Allied Market Research published a new report, titled, "Feedback Management Software Market Growing with CAGR of 12.9% Reach USD 28.7 Billion by 2031 ." The report offers an extensive analysis of key growth strategies, drivers, opportunities, key segment, Porter's Five Forces analysis, and competitive landscape. This study is a helpful source of information for market players, investors, VPs, stakeholders, and new entrants to gain thorough understanding of the industry and

All 5 Releases


More Releases for Behring

Hyperimmune Globulins Market Is Going to Boom |• CSL Behring • Grifols
According to Worldwide Market Reports (WMR) highlights that the "Hyperimmune Globulins Market" is projected to experience substantial growth in the coming years. This report provides a comprehensive analysis of the market landscape using an integrated approach that includes research methodology, market size evaluation, data compilation, and insights gathered from multiple credible sources. The study covers critical market elements such as market dynamics, drivers, restraints, challenges, threats, growth opportunities, development trends, technological
Hemorrhagic Shock Treatment Market Deep Research Report - CSL Behring, Octapharm …
Hemorrhagic Shock Treatment Market Insights Hemorrhagic Shock Treatment Market is estimated to be valued at USD 224.6 Mn in 2025 and is expected to reach USD 303.6 Mn in 2032, exhibiting a compound annual growth rate (CAGR) of 4.4% from 2025 to 2032. Coherent Market Insights has published a new comprehensive analysis on the Hemorrhagic Shock Treatment Market (2025-2032), focusing on critical transformations in the U.S. healthcare environment. This report highlights essential
Antibody-mediated Rejection Market Growth Projections 2024-2034: DelveInsight An …
The Key Antibody-mediated Rejection Companies in the market include - CSL Behring, Hansa Biopharma, Horizon Therapeutics, Sanofi, Farsad Eskandary, Bristol-Myers Squibb, Janssen, LP, Alexion, and others. DelveInsight's "Antibody-mediated Rejection Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Antibody-mediated Rejection, historical and forecasted epidemiology as well as the Antibody-mediated Rejection market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know
Huge Growth on Stimate Market 2021-2027| CSL Behring, Sanofi
Global Stimate Market research report is detailed businesses think about on the present state of the industry which studies innovative strategies for business growth and defines important factors such as top players, manufacture value, key regions, growth rate, suppliers, SWOT analysis i.e. Strength, Weakness, Opportunities, and Threat to the organization and others. The competitive landscape is a critical aspect every key player needs to be familiar with. The report throws light
Hyperimmune Globulins Market Outlook and Research| CSL Behring, Grifols, Biotest
Hyperimmune globulin is similar to intravenous immunoglobulin (IVIG) except that it is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. This is in contrast to vaccines that provide "active" immunity. However, vaccines
Myasthenia Gravis Therapeutics Analysis Alexion Pharmaceuticals, Inc., CSL Behri …
The study analysed that the therapeutics pipeline comprises of approximately 19 drug candidates in different stages of development. Myasthenia gravis is a chronic autoimmune disorder that acts on neuromuscular junction and leads to the weakening of skeletal muscles. This causes loss of muscle control in moving the body parts, such as the movement of arms and legs, breathing, loss of eye movements, chewing, talking, and swallowing. The situation of the disease